11/19/2013

Change in the responsibility areas of Orion Group Executive Management Board as of 1 January 2014

 
 

ORION CORPORATION        STOCK EXCHANGE RELEASE 19 NOVEMBER 2013 at 12:10 p.m.  EET              

 
The following change has been made in the responsibility areas of Orion Group Executive Management Board as of 1 January 2014:

Mr. Markku Huhta-Koivisto, Senior Vice President responsible for Specialty Products and Fermion business divisions and Dr. Liisa Hurme, Senior Vice President responsible for Proprietary Products business division will exchange their responsibility areas. Thus, as of 1 January 2014, Markku Huhta-Koivisto, Senior Vice President, will be responsible for Proprietary Products business division, and Liisa Hurme, Senior Vice President, will be responsible for Specialty Products and Fermion business divisions.

They both continue to be members of the Orion Group Executive Management Board as previously.

Timo Lappalainen, President and CEO, says:

"I am pleased that we can develop the Executive Management Board's operations in a flexible way by this exchange of responsibility areas. I believe that the change will give, not only a good possibility for Liisa and Markku for job rotation, but also that it will bring positive effects for the whole Executive Management Board and the company."

Orion Corporation

Timo Lappalainen
President and CEO
    Olli Huotari
SVP, Corporate Functions


Contact person:

Timo Lappalainen, President and CEO, phone: +358 50 966 3692

     
    
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.